November 4, 2025 — Pfizer Inc. (NYSE: PFE) has released its third-quarter 2025 financial results, reaffirming its 2025 revenue guidance and raising its adjusted diluted EPS guidance.
Pfizer Chairman and CEO Dr. Albert Bourla expressed pride in the company’s agreement with the U.S. Government, believing it provides greater business clarity. He also highlighted strategic actions aimed at advancing innovation and addressing medical needs in high-growth markets.
CFO and EVP David Denton noted the company’s focus on execution and financial discipline, underscoring confidence in delivering strong shareholder results through the raised EPS guidance.
Key results include third-quarter revenues of $16.7 billion, a 7% year-over-year operational decline, and a 4% operational revenue growth in the non-COVID portfolio. Reported diluted EPS stood at $0.62, with adjusted diluted EPS at $0.87.
The company reaffirms its full-year revenue guidance of $61.0 to $64.0 billion and raises the adjusted diluted EPS guidance to a range of $3.00 to $3.15. Pfizer remains on track to achieve approximately $7.2 billion in net cost savings by the end of 2027 through previously announced cost improvement initiatives.
Contact:
Source: Pfizer Inc.
